Recent advances in our understanding of T-cell biology suggest that IL-2Rα/β/γ engagement by IL-2 on tumor-specific CD8 + T-cell subsets is essential for optimal CD8 + T-cell priming, “better effector” T-cell differentiation and antitumor immunity [75–77]. Here, CD8A is linked to neoplasm.